FDA Brief

Warning letters Drugs

FDA warning letter to

Rhyz Analytical Labs

High riskIssued Nov 12, 2025Posted Dec 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.

What happened

FDA inspected Rhyz Analytical Labs in Provo, Utah, from June 2 to 5, 2025. It found the contract testing laboratory repeatedly accepted “unknown laboratory error” or “contamination of an unknown source” as root causes for microbial test failures in at least five investigations, relied on retests without adequate investigation, and lacked adequate quality-unit procedures and oversight. FDA reviewed the firm’s June 25, 2025, response and called it inadequate.

What FDA found

  1. The firm did not thoroughly investigate unexplained discrepancies or batch failures, including multiple microbial test failures.

    21 CFR 211.192
  2. It repeatedly accepted “unknown laboratory error” and “contamination of an unknown source” as root causes in at least five investigations without enough scientific justification.

    21 CFR 211.192
  3. It relied on retest data without adequately investigating the potential contamination source before retesting.

    21 CFR 211.192
  4. It did not assess the effectiveness of its corrective and preventive actions.

    21 CFR 211.192
  5. It failed to establish adequate written responsibilities and procedures for the quality control unit.

    21 CFR 211.22(d)
  6. Its quality unit failed to adequately oversee contract testing operations, including procedures for deviations, change control, cleaning, and laboratory investigations.

    21 CFR 211.22(d)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days, including a three-year retrospective review of invalidated out-of-specification results for U.S. products and remediation plans for its OOS investigation and quality systems. If it cannot complete corrective actions in that time, it must state why and give a schedule.

Who should pay attention

  • drug companies that use Rhyz as a contract testing laboratory
  • OTC drug brands relying on its test results
  • quality teams auditing contract lab vendors

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  3. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  4. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk